Did anyone see the article about UB-421 antibody from Taiwanese company. Seems similar mechanism to leronlimab, but inferior because requires IV infusion over 1 hour in clinic or hospital. Not sure why this was in news and and the NEJM and we are not. This makes no sense. Even Tony Fauci, head of NIH is commenting, but he has never said anything about us. And this was only 16 week phase 2 from a foreign company?

This is a joke.